Results 171 to 180 of about 802,486 (287)

Analysis of hepatitis B virus integration identifies KMT2B as a novel cancer-related gene in pancreatic cancer. [PDF]

open access: yesClin Transl Med
Li M   +16 more
europepmc   +1 more source

Hepatitis B Virus [PDF]

open access: yesTransfusion Medicine and Hemotherapy, 2000
openaire   +2 more sources

Tislelizumab: Structural Innovations and Expanding Clinical Horizons in Next‐Generation PD‐1 Immunotherapy

open access: yesChronic Diseases and Translational Medicine, EarlyView.
The interaction of tislelizumab with PD‐1/PD‐L1 in the tumor microenvironment. Tislelizumab targets PD‐1 on T cells, blocking its interaction with PD‐L1 on tumor cells. This action is facilitated by a modified F(ab) region that limits Fc‐γ receptor binding, thereby enhancing the antitumor immune response. ABSTRACT Tislelizumab is a next‐generation PD‐1
Thy T. Nguyen   +4 more
wiley   +1 more source

Identification of genes associated with hepatitis B virus infection and breast cancer tumorigenesis and progression. [PDF]

open access: yesBiochem Biophys Rep
Zhou M   +8 more
europepmc   +1 more source

Mechanisms of Hepatitis B Virus Persistence.

open access: yesTrends in Microbiology, 2018
Kuen-Nan Tsai, C. Kuo, J. Ou
semanticscholar   +1 more source

Asymmetric Total Synthesis of (−)‐Glycybridin B, a Pharmacophore Screened Candidate for Tubulin Binding

open access: yesChemistry – A European Journal, EarlyView.
Discovery and first total synthesis of (−)‐glycybridin B via a five‐step route utilizing a key chalcone intermediate. Initially identified through a pharmacophore screening as a potential tubulin binder, this natural product serves as a tool compound to explore structure‐activity relationships related to microtubule targeting and anticancer potential ...
Alice Maiocchi   +14 more
wiley   +1 more source

Hepatitis B virus reactivation in patients with hematologic malignancies treated with Bruton tyrosine kinase inhibitors. [PDF]

open access: yesBlood Res
Hur JY   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy